Agilent to Sell $750M in Notes | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it would offer $750 million worth of senior notes through two offerings.

The firm has not filed a final prospectus yet on the offerings. However, in a statement, Agilent said that it would use the proceeds to satisfy, in part, the financing obligation of Agilent Technologies World Trade, the subsidiary that acquired Varian for $1.5 billion in May.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.